Oral anti-diabetic drugs

Description

• VOLIPHAGE-M contains two oral anti-hyperglycaemic drugs; Voglibose and Metformin hydrochloride used in the management of Type 2 Diabetes. Voglibose inhibits the activity of Alpha-glucosidases in the intestine, thereby delaying the digestion and absorption of carbohydrates, resulting in an improvement of postprandial hyperglycaemia. The primary mechanism of action of Metformin hydrochloride is to reduce fasting plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
• Hence, the combination of Voglibose and Metformin hydrochloride complement each other and provide better glycaemic control in the management of Type 2 Diabetes and may help prevent its associated macrovascular and microvascular complications.

Indications

• VOLIPHAGE-M is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with Type 2 Diabetes, who are already treated with voglibose and metformin as individual drugs or whose diabetes is not adequately controlled with metformin alone or for those patients who have initially responded to voglibose alone and require additional glycaemic control.

Dosage

• Dosage should be individualized on the basis of both effectiveness and tolerance. The initial recommended dose is one tablet of VOLIPHAGE-M 0.2 ^ 1 three times daily just before each meal. In case of inadequate effect, the dose may be increased up to 1 tablet of VOLIPHAGE-M 0.3 three times daily just before each meal.
• Patients Switching from Combination Therapy of Voglibose plus Metformin Administered as Separate Tablets of VOLIPHAGE-M 0.2 or VOLIPHAGE-M 0.3 may be initiated based on the dose of voglibose and metformin already being taken.